Data from Phase 3b ENSURE-AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban)in Patients with Atrial Fibrillation Und

MUNICH, August 24, 2016 /PRNewswire/ --

- ENSURE-AF results to be featured during a late-breaking clinical trial session  
- Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study
to be presented 
- Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient
registries 

Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today announced the presentation of 13 abstracts at the ESC Congress 2016, taking place from August 27-31 in Rome, Italy. The first results from ENSURE-AF, the largest prospective randomized clinical trial to date evaluating a non-vitamin K antagonist oral anticoagulant (NOAC) compared to a current standard of care in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion, which included nearly 2,200 patients from 19 countries, will be featured in a late-breaking clinical trial presentation. In addition, five analyses from the global phase 3 ENGAGE AF-TIMI 48 study of edoxaban (known by the brand name LIXIANA(R) outside the US and SAVAYSA(R) in the US) will be presented, including clinical outcomes associated with dose interruption in patients with NVAF compared to warfarin, relationship between body mass index and clinical outcomes, and a novel risk prediction score for net clinical outcome assessment.

Furthermore, six analyses from the PREFER in atrial fibrillation (AF) registry and one analysis from the PREFER in venous thromboembolism (VTE) registry will be presented, with new insights into the use of NOAC therapy, including prescribing patterns and trends in acute and long-term management of patients with AF and VTE.

Details of the presentations are included below:

(CONTINUA)